Sun Pharma and Philogen Team Up to Fight Cancer with New Drug Fibromun

Sun Pharmaceutical Industries Limited (Sun Pharma) and Philogen S.p.A (Philogen) have announced a global exclusive agreement to commercialize Fibromun (L19TNF), an anti-cancer immunotherapy product. Fibromun is currently being tested in trials for treating soft tissue sarcoma and glioblastoma, which are cancers with significant unmet medical needs.

Under this agreement, Sun Pharma will have exclusive global rights to commercialize Fibromun, while Philogen will continue conducting clinical trials, seek marketing authorization, and manufacture the product. The companies will share post-commercialization profits, with Sun Pharma receiving 55% and Philogen 45%.

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, expressed optimism about Fibromun's potential, stating, "Fibromun's progress through development has been quite encouraging and it has potential to be an important option for treatment of soft-tissue sarcomas and other cancers with significant unmet medical needs."

Prof. Dr. Dario Neri, CEO and CSO of Philogen, added, "We are pleased to extend our collaboration with Sun Pharma. Our data has shown that Fibromun has promising therapeutic activity, especially in glioblastoma, inducing long-lasting anti-tumor responses in some patients."

This is the second collaboration between Sun Pharma and Philogen, following their May 30, 2023 agreement to commercialize Nidlegy, a product aimed at treating locally advanced melanoma, in Europe, Australia, and New Zealand. The first Marketing Authorization Application for Nidlegy has already been submitted to the European Medicines Agency (EMA).